@emeneque12 @o__livier @GilbertDeray Quelques exemples : merci de cesser la désinformation https://t.co/2gPWVegBJG
Vaccin Russe : https://t.co/47b6pjUzo6 Cansino Phase 1 : https://t.co/agLUS3aLID Cansino Phase 2 : https://t.co/FBrFp87AL8 Et les essais de phase III sont en cours, il faut tout simplement attendre et arrêter d'alimenter les thèses paranoïaques
@SatWgat @NEJM T.ex. såg man i CanSino:s studie att de med tecken på hög (52% av deltagarna) pre-existerande immunitet mot Ad5(-vektorn) hade 2-3 gånger lägre nivåer av neutraliserande antikroppar efter vaccinering: https://t.co/dOhQ6OBWBZ
RT @Pediatria: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or ol…
RT @ncholiA: @timbooth75 @tadonafilsitrat @eSrA_Saglam_T @OxfordVacGroup @AstraZeneca CanSino (Çin) ve Sputnik V (Rus) aşısı Ad5 vektörünü…
@Ulivillalobos @joluisgarcia @AnaMafud @gaby_lozoyag @_LASNOTICIASMTY Buen día! Resultados fase 2 vacuna China ConSino Biológicas usando Adenovirus con replicación deficiente 100,000,000,000 partículas 1ra dosis, 50,000 000 000 2da dosis https://t.co/N8FLP
@Incitatum @hildabast A key difference could be the population group. This study https://t.co/brXRTioGui showed that preexisting ad5 antibodies reduced efficacy for that vaccine. I wonder if a similar effect applies to the ChAdOx vector (which could in tur
@ArisKatzourakis @myrtani The CanSino vaccine which is based on Ad5 had possibly issues related to preexisrint immunity against adeno https://t.co/eTpyCSYdPQ
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial https://t.co/GHIsFiaxAD
Fase 2 mostrou boas taxas de soroconversão entre os participantes (96%), confirmando dados anteriores e apontando uma resposta imunológica forte contra o SARS-CoV-2, em paralelo a um bom perfil de segurança. https://t.co/HTnS9Sz32I
Sars 8 https://t.co/eOPlJGo8To
@Esteban1138 Aquí links: Gamaleya Research Institute (Rusia) primeros resultados 1/2: https://t.co/4Hbk7Xhe4b CansinoBio (China) Fase 1: https://t.co/4asYn9ymHX CansinoBio (China) Fase 2: https://t.co/PM8KSE5Cry
RT @donni__69: Han publicado los resultados de las Fases 1-2 realizado en Wuhan que han demostrado que es segura e induce inmunidad en el 8…
“Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial - PubMed” https://t.co/tusrUVTr7n
@telediariomty @Arq_Benavides @AlizVeraOficial @multimediostv Resultados fase 2 vacuna China ConSino Biologicas Adenovirus deficiente replicación 100,000,000,000 partículas primera dosis 50,000 000 000 2da dosis https://t.co/N8FLPxkdij
RT @sergioassia: La vacuna contra el #COVID__19 producida en #China , en estudios de fase 2, ha mostrado ser segura y protectora, vamos por…
RT @sergioassia: La vacuna contra el #COVID__19 producida en #China , en estudios de fase 2, ha mostrado ser segura y protectora, vamos por…
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet https://t.co/hAtZNy481J
RT @sergioassia: La vacuna contra el #COVID__19 producida en #China , en estudios de fase 2, ha mostrado ser segura y protectora, vamos por…
RT @sergioassia: La vacuna contra el #COVID__19 producida en #China , en estudios de fase 2, ha mostrado ser segura y protectora, vamos por…
RT @sergioassia: La vacuna contra el #COVID__19 producida en #China , en estudios de fase 2, ha mostrado ser segura y protectora, vamos por…
RT @sergioassia: La vacuna contra el #COVID__19 producida en #China , en estudios de fase 2, ha mostrado ser segura y protectora, vamos por…
RT @sergioassia: La vacuna contra el #COVID__19 producida en #China , en estudios de fase 2, ha mostrado ser segura y protectora, vamos por…
RT @sergioassia: La vacuna contra el #COVID__19 producida en #China , en estudios de fase 2, ha mostrado ser segura y protectora, vamos por…
RT @sergioassia: La vacuna contra el #COVID__19 producida en #China , en estudios de fase 2, ha mostrado ser segura y protectora, vamos por…
RT @sergioassia: La vacuna contra el #COVID__19 producida en #China , en estudios de fase 2, ha mostrado ser segura y protectora, vamos por…
👏🏼
RT @sergioassia: La vacuna contra el #COVID__19 producida en #China , en estudios de fase 2, ha mostrado ser segura y protectora, vamos por…
RT @sergioassia: La vacuna contra el #COVID__19 producida en #China , en estudios de fase 2, ha mostrado ser segura y protectora, vamos por…
RT @sergioassia: La vacuna contra el #COVID__19 producida en #China , en estudios de fase 2, ha mostrado ser segura y protectora, vamos por…
RT @sergioassia: La vacuna contra el #COVID__19 producida en #China , en estudios de fase 2, ha mostrado ser segura y protectora, vamos por…
👏👏
RT @sergioassia: La vacuna contra el #COVID__19 producida en #China , en estudios de fase 2, ha mostrado ser segura y protectora, vamos por…
😷
La vacuna contra el #COVID__19 producida en #China , en estudios de fase 2, ha mostrado ser segura y protectora, vamos por buen camino. https://t.co/6C9zsyMCWP
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial https://t.co/qnIMfnaGPC
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial https://t.co/SfTJihyvgw
Sars 2 science https://t.co/eOPlJGo8To
RT @pmarsupia: 🔴 Más buenas noticias! The Lancet también ha publicado los resultados de la Fase II de la farmacéutica china CanSino (sí,…
@FernandoMencar1 @g1 Os diplomatas chineses não precisam de máscaras quando visitam a Europa. Todos os soldados chineses são vacinados e também fazem parte dos voluntários. Eles usam a vacina Ad5-nCoV. resultado muito bom. https://t.co/lkv1sbPKOs
RT @Despierta_1: @mlgomezmartin @mavidonate @Jaime_CastroG @telediario_tve Aquí las tienes Cansino Phase I: https://t.co/7RDHtu8VlF Cansino…
@mlgomezmartin @mavidonate @Jaime_CastroG @telediario_tve Aquí las tienes Cansino Phase I: https://t.co/7RDHtu8VlF Cansino Phase II: https://t.co/WiCbcndL54 Sinovac en animales: https://t.co/tAwwJ6ZH9J Sinovac Phase II: https://t.co/PxjNzAjcbd Sinopharm e
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
@Fer137xyz @Malthael02 porque tengo entendido que la tasa alta de reacciones negativas es falsa: https://t.co/aaF6inlztf Y que los estudios reportan tasas muy pequeñas https://t.co/g7KdNDEjVF https://t.co/eKnsdGZhuf
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
RT @amitsurg: They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study publishe…
They tried to cover it up by claiming it induced cellular immunity and not antibody response. However in their study published in Lancet, Chinese researchers had claimed 96% antibody response for the vaccine and said nothing about cellular immunity. https:
RT @carpe_diem0820: 中国のCansinoが開発するCOVID-19ワクチン、感冒ウイルスであるアデノウイルス(Ad5)抗体を既に持つ人では免疫原性が低くなることから、1→2回接種での効果を評価へ A Chinese vaccine maker will t…
RT @carpe_diem0820: 中国のCansinoが開発するCOVID-19ワクチン、感冒ウイルスであるアデノウイルス(Ad5)抗体を既に持つ人では免疫原性が低くなることから、1→2回接種での効果を評価へ A Chinese vaccine maker will t…
中国のCansinoが開発するCOVID-19ワクチン、感冒ウイルスであるアデノウイルス(Ad5)抗体を既に持つ人では免疫原性が低くなることから、1→2回接種での効果を評価へ A Chinese vaccine maker will try a two-dose regimen after concerns that one dose was ineffective. https://t.co/BfcAztlYaY https://t.co/iJMHd6oUxR
RT @aharrasi1: بعد نشر نتائج اللقاحين الصيني ولقاح جامعة أكسفورد، ذي لانسيت تنشر نتائج الدراسات السريرية 1 و2 للقاح الروسي باستخدام نوعين م…
RT @aharrasi1: بعد نشر نتائج اللقاحين الصيني ولقاح جامعة أكسفورد، ذي لانسيت تنشر نتائج الدراسات السريرية 1 و2 للقاح الروسي باستخدام نوعين م…
CanSinoBio has an adenovirus 5 vaccine. Phase 1/2: https://t.co/fJsw5SwyKQ Phase 3 design: https://t.co/9faku7qurE https://t.co/aqILcBrLEL
@Gordon_dyce @zbysfedo Sorry - late at night here & I'm tired. And too tired to do what I'd normally do - which is dig out links to show the level of moderate-severe AEs is unusually high. Here an example to make amends for earlier testiness: CanSino's
@waqasahmad_pk @Asad_Umar @ImranKhanPTI @PakPMO CanSino Ph.II results showing safety & efficacy were published in renowned medical journal 'The Lancet' a few months ago, with only minor side-effects, thus it is perfectly safe to proceed to Ph.III trial
@disishus @Asad_Umar Correct, immunogenicity & safety was proven in humans, sufficient to proceed to 3rd Phase: https://t.co/i9h5p9o03v
@LigandR @Asad_Umar 1. No, as usual animal model trials happen way before any humans are involved in testing a new drug. 2. They shared data with the world by publishing Ph.II results in 'The Lancet', showing this candidate is safe & efficacious enough
@ShamaKh84025358 @Asad_Umar @SouthAsiaPress @Anthony_Klan It's the same CanSino adenovirus vector vaccine approved for (& presumably already widely used in) the Chinese military since 25th June: https://t.co/wfReqdiEwQ Here's the result of its success
The original data: https://t.co/AFNIwMFU46
RT @HedgeyeHC: $MRNA #CovidVaccine $AZN Adenovirus vector side effects... "Immunogenicity and safety of a recombinant adenovirus type-5-ve…
$MRNA #CovidVaccine $AZN Adenovirus vector side effects... "Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial" htt
RT @alejandropg11: @MorenoDA3 @mavidonate Las publicaciones: Cansino,Fase I: https://t.co/yJftsR0KhZ Cansino,Fase II: https://t.co/qrcft9sn…
RT @alejandropg11: @MorenoDA3 @mavidonate Las publicaciones: Cansino,Fase I: https://t.co/yJftsR0KhZ Cansino,Fase II: https://t.co/qrcft9sn…
RT @alejandropg11: @MorenoDA3 @mavidonate Las publicaciones: Cansino,Fase I: https://t.co/yJftsR0KhZ Cansino,Fase II: https://t.co/qrcft9sn…
@MorenoDA3 @mavidonate Las publicaciones: Cansino,Fase I: https://t.co/yJftsR0KhZ Cansino,Fase II: https://t.co/qrcft9snRa Sinopharm,en animales: https://t.co/8IoyAzj8tU Sinopharm,Fase I/II: https://t.co/tOFKFwcOdR Sinovac,en animales: https://t.co/UMXCuU
RT @aharrasi1: بعد نشر نتائج اللقاحين الصيني ولقاح جامعة أكسفورد، ذي لانسيت تنشر نتائج الدراسات السريرية 1 و2 للقاح الروسي باستخدام نوعين م…
Prior CanSino Trial: https://t.co/brXRTioGui
RT @aharrasi1: بعد نشر نتائج اللقاحين الصيني ولقاح جامعة أكسفورد، ذي لانسيت تنشر نتائج الدراسات السريرية 1 و2 للقاح الروسي باستخدام نوعين م…
RT @aharrasi1: بعد نشر نتائج اللقاحين الصيني ولقاح جامعة أكسفورد، ذي لانسيت تنشر نتائج الدراسات السريرية 1 و2 للقاح الروسي باستخدام نوعين م…
RT @aharrasi1: بعد نشر نتائج اللقاحين الصيني ولقاح جامعة أكسفورد، ذي لانسيت تنشر نتائج الدراسات السريرية 1 و2 للقاح الروسي باستخدام نوعين م…
RT @aharrasi1: بعد نشر نتائج اللقاحين الصيني ولقاح جامعة أكسفورد، ذي لانسيت تنشر نتائج الدراسات السريرية 1 و2 للقاح الروسي باستخدام نوعين م…
RT @aharrasi1: بعد نشر نتائج اللقاحين الصيني ولقاح جامعة أكسفورد، ذي لانسيت تنشر نتائج الدراسات السريرية 1 و2 للقاح الروسي باستخدام نوعين م…
@ashishkjha This study showed that dose of 5*10^10 was tolerable/safe, only one had adverse effect https://t.co/EH2TWsyQ4T
RT @aharrasi1: بعد نشر نتائج اللقاحين الصيني ولقاح جامعة أكسفورد، ذي لانسيت تنشر نتائج الدراسات السريرية 1 و2 للقاح الروسي باستخدام نوعين م…
RT @aharrasi1: بعد نشر نتائج اللقاحين الصيني ولقاح جامعة أكسفورد، ذي لانسيت تنشر نتائج الدراسات السريرية 1 و2 للقاح الروسي باستخدام نوعين م…
RT @aharrasi1: بعد نشر نتائج اللقاحين الصيني ولقاح جامعة أكسفورد، ذي لانسيت تنشر نتائج الدراسات السريرية 1 و2 للقاح الروسي باستخدام نوعين م…
RT @aharrasi1: بعد نشر نتائج اللقاحين الصيني ولقاح جامعة أكسفورد، ذي لانسيت تنشر نتائج الدراسات السريرية 1 و2 للقاح الروسي باستخدام نوعين م…
RT @aharrasi1: بعد نشر نتائج اللقاحين الصيني ولقاح جامعة أكسفورد، ذي لانسيت تنشر نتائج الدراسات السريرية 1 و2 للقاح الروسي باستخدام نوعين م…
RT @aharrasi1: بعد نشر نتائج اللقاحين الصيني ولقاح جامعة أكسفورد، ذي لانسيت تنشر نتائج الدراسات السريرية 1 و2 للقاح الروسي باستخدام نوعين م…
RT @aharrasi1: بعد نشر نتائج اللقاحين الصيني ولقاح جامعة أكسفورد، ذي لانسيت تنشر نتائج الدراسات السريرية 1 و2 للقاح الروسي باستخدام نوعين م…